1. Home
  2. OFRM vs MNPR Comparison

OFRM vs MNPR Comparison

Compare OFRM & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

OFRM

Once Upon a Farm PBC

N/A

Current Price

$17.13

Market Cap

684.3M

Sector

N/A

ML Signal

N/A

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

N/A

Current Price

$107.05

Market Cap

587.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OFRM
MNPR
Founded
2015
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
684.3M
587.4M
IPO Year
2025
2019

Fundamental Metrics

Financial Performance
Metric
OFRM
MNPR
Price
$17.13
$107.05
Analyst Decision
Buy
Strong Buy
Analyst Count
9
11
Target Price
$27.75
$107.00
AVG Volume (30 Days)
441.3K
266.7K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
54.99
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$29.42
N/A
Revenue Next Year
$34.69
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.00
$29.18
52 Week High
$27.00
$124.82

Technical Indicators

Market Signals
Indicator
OFRM
MNPR
Relative Strength Index (RSI) 48.98 47.33
Support Level $14.42 $102.88
Resistance Level $17.17 $114.60
Average True Range (ATR) 1.09 6.71
MACD 0.07 -1.60
Stochastic Oscillator 55.56 12.57

Price Performance

Historical Comparison
OFRM
MNPR

About OFRM Once Upon a Farm PBC

Once Upon a Farm PBC is a provider of baby food products. The company provides childhood nutrition with real, organic, farm-fresh food-made with no added sugar, no preservatives, and nothing artificial. Its products are available at retail customers, including Target, Whole Foods, Kroger, Walmart, Publix, and Wegmans. Its key products include Smoothies, Yogurt, Milk Shakes, Oat Bars, etc.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

Share on Social Networks: